Location History:
- Cambridge, MA (US) (2019)
- Lexington, MA (US) (2024)
Company Filing History:
2 out of 3,923 
1 out of 2,893 
Years Active: 2019-2024
Title: Hui-Qin Wang: Innovator in Pharmaceutical Combinations
Introduction
Hui-Qin Wang is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug combinations. With a total of 2 patents, his work focuses on addressing proliferative diseases through advanced therapeutic methods.
Latest Patents
Hui-Qin Wang's latest patents include a pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor. This combination is designed for simultaneous or sequential administration, aimed at treating proliferative diseases. Additionally, he has developed another pharmaceutical combination involving an mdm2/4 inhibitor and a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. These inventions highlight his commitment to advancing treatment options in the pharmaceutical industry.
Career Highlights
Throughout his career, Hui-Qin Wang has worked with prominent organizations such as Novartis AG and The General Hospital Corporation. His experience in these institutions has allowed him to collaborate with leading experts in the field, further enhancing his contributions to pharmaceutical research.
Collaborations
Hui-Qin Wang has collaborated with notable colleagues, including Fang Li and Stephane Ferretti. These partnerships have played a crucial role in the development of his innovative pharmaceutical combinations.
Conclusion
Hui-Qin Wang's work in pharmaceutical innovations demonstrates his dedication to improving treatment options for patients with proliferative diseases. His patents reflect a significant advancement in the field, showcasing the potential of combining various therapeutic agents for enhanced efficacy.